The targets for antibodies include tumor specific antigens such as human epidermal growth factor receptor 2 (HER2) expressed on breast cancer cells that is recognized by Trastuzumab, and immune suppressive molecules such as programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) recognized by Nivolmab and Pembrolizumab, respectively. Here, ERBB2 is linked to neoplasm.